15 Apr , 2025 By : Debdeep Gupta
Zydus Lifesciences share price extended the gains on second day, rising 1 percent in the early trade on April 15 following United States Food and Drug Administration (USFDA) approval for Jaythari (Deflazacort) tablets.
At 09:21am, Zydus Lifesciences was quoting at Rs 878.05, up Rs 9.80, or 1.13 percent, on the BSE.
The drug maker will produce Jaythari (Deflazacort) 6 mg, 18 mg, 30 mg and 36 mg tablets at Doppel Farmaceutici S.r.l., Italy facility, company said in exchange filing.
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.
The group now has 424 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus MedTech, a wholly owned subsidiary of the company has incorporated a wholly owned subsidiary in the name of Zydus MedTech (France) SAS on April 10, 2025.
The share touched a 52-week high of Rs 1,323.90 and a 52-week low of Rs 797.05 on 09 August, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 33.68 percent below its 52-week high and 10.16 percent above its 52-week low.
Market capitalisation stands at Rs 88,352.38 crore.9 months.
0 Comment